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Towards a strategy for malaria 
in pregnancy in Afghanistan: analysis of clinical 
realities and women’s perceptions of malaria 
and anaemia
Natasha Howard1* , Sayed Enayatullah2, Nader Mohammad3, Ismail Mayan3, Zohra Shamszai4, 
Mark Rowland1,2 and Toby Leslie2,3
Abstract 
Background: Afghanistan has some of the worst maternal and infant mortality indicators in the world and malaria is 
a significant public health concern. Study objectives were to assess prevalence of malaria and anaemia, related knowl-
edge and practices, and malaria prevention barriers among pregnant women in eastern Afghanistan.
Methods: Three studies were conducted: (1) a clinical survey of maternal malaria, maternal anaemia, and neonatal 
birthweight in a rural district hospital delivery-ward; (2) a case–control study of malaria risk among reproductive-age 
women attending primary-level clinics; and (3) community surveys of malaria and anaemia prevalence, socioeco-
nomic status, malaria knowledge and reported behaviour among pregnant women.
Results: Among 517 delivery-ward participants (1), one malaria case (prevalence 1.9/1000), 179 anaemia cases 
(prevalence 346/1000), and 59 low-birthweight deliveries (prevalence 107/1000) were detected. Anaemia was not 
associated with age, gravidity, intestinal parasite prevalence, or low-birthweight at delivery. Among 141 malaria cases 
and 1010 controls (2), no association was found between malaria infection and pregnancy (AOR 0.89; 95 % CI 0.57–
1.39), parity (AOR 0.95; 95 % CI 0.85–1.05), age (AOR 1.02; 95 % CI 1.00–1.04), or anaemia (AOR 1.00; 95 % CI 0.65–1.54). 
Those reporting insecticide-treated net usage had 40 % reduced odds of malaria infection (AOR 0.60; 95 % CI 0.40–
0.91). Among 530 community survey participants (3), malaria and anaemia prevalence were 3.9/1000 and 277/1000 
respectively, with 34/1000 experiencing severe anaemia. Despite most women having no formal education, malaria 
knowledge was high. Most expressed reluctance to take malaria preventive medication during pregnancy, deeming it 
potentially unsafe.
Conclusions: Given the low malaria risk and reported avoidance of medication during pregnancy, intermittent pre-
ventive treatment is hard to justify or implement. Preventive strategy should instead focus on long-lasting insecticidal 
nets for all pregnant women.
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Background
Infection with Plasmodium falciparum or Plasmodium 
vivax can be dangerous in pregnancy, increasing risks 
of severe anaemia, premature delivery, low-birthweight, 
and foetal, neonatal and maternal death [1, 2]. Falcipa-
rum infection in pregnancy causes up to approximately 
10,000 maternal deaths, 3–8 % infant deaths, and 8–14 % 
low-birthweight (LBW) deliveries annually, and preg-
nant women are often prioritized for preventive inter-
ventions including long-lasting insecticidal nets (LLINs) 
and intermittent preventive treatment (IPT) [3, 4]. In 
unstable transmission settings, such as much of South 
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Asia, pregnant women experience 2–3× higher risk than 
non-pregnant women of developing severe malaria or 
malaria-related severe anaemia [2, 4–6].
Malaria in pregnancy is most studied for falciparum 
infection in sub-Saharan Africa and Southeast Asia [3, 
7, 8]. Though less documented, growing literature on 
vivax infection in pregnancy indicates considerable risk 
and approximately 71 million pregnancies in vivax-
endemic areas globally [1, 4, 6, 9–15]. Plasmodium vivax 
is the most geographically widespread human malaria 
parasite—endemic in much of Asia, including Afghani-
stan, with approximately 2.9 billion people at risk glob-
ally [15–19]. It has been associated with severe clinical 
manifestations in pregnancy, including severe anaemia, 
thrombocytopenia, miscarriage, low-birthweight, and 
preterm delivery [1, 4, 19, 20]. Though in  vivo P. vivax 
placental sequestration has not been identified, in  vitro 
evidence exists of cytoadherence to placental glycosa-
minoglycans [21]. Relapsing infections from hypnozoite 
reservoirs cannot be treated effectively, as primaquine is 
contraindicated in pregnancy, making prevention prefer-
able [22].
Afghanistan has received considerable international 
attention and support since the Taliban government 
ended in 2001, but remains a fragile country [23, 24]. 
The estimated maternal mortality ratio reduced from 
1300/100,000 in 2000 to 460/100,000 in 2010 [25]. Simi-
larly, the infant mortality rate reduced from 153/1000 
to 74/1000 in 2011 [26, 27]. However, indicators remain 
poor. An estimated 16 million people are at risk of 
malaria in Afghanistan and it remains a public health 
concern [28, 29]. Transmission is unstable and seasonal, 
and a significant cause of morbidity in lowland and rice 
irrigation areas [29].
No publications were found on malaria epidemiology 
in pregnancy in Afghanistan. This study aimed to assess 
the contribution of malaria to maternal anaemia and 
birth outcomes in eastern Afghanistan. Objectives were 
to assess: (1) prevalence of malaria and anaemia among 
pregnant women, (2) risks of malaria in pregnancy, and 
(3) malaria awareness and reported behaviours during 
pregnancy.
Methods
Study site and population
Studies were conducted in Ghani Khel District Hospital, a 
secondary-level facility in rural Nangarhar province, and 
primary-level facilities and communities within its catch-
ment area  (Fig.  1). The target population was women 
of reproductive age (WRA; aged 15–49) from among 
an estimated population of 500,000 women access-
ing health services subcontracted to an NGO provider, 
HealthNet-TPO, through Afghanistan’s Basic Package 
of Health Services [30]. Malaria transmission is moder-
ate and seasonal, vivax peaking May–August and caus-
ing 70–95  % of malaria, and falciparum predominantly 
in October–November [31]. Main vectors are Anopheles 
stephensi, Anopheles superpictus, and Anopheles culicifa-
cies [29, 31]. At the time of this study, insecticide-treated 
nets (e.g. ITNs/LLINs)—targeted preferentially to preg-
nant women—were distributed at subsidized prices 
through primary-level facilities [32, 33].
Study design and data collection
Three complementary studies were conducted: (1) a clini-
cal survey of maternal malaria, maternal anaemia, and 
neonatal birthweight in the district hospital (2) a case–
control study of malaria risk factors among WRA attend-
ing nearby primary-level facilities, and (3) a two-round 
community survey of malaria and anaemia prevalence, 
socioeconomic status and related knowledge, attitudes 
and practices among pregnant women in four nearby 
districts.
Delivery‑ward survey
Women and chaperones were informed and asked about 
participation during ward admission, and those giving 
informed consent were enrolled and examined between 
February and December 2004: (1) thick and thin Giemsa-
stained blood smears of peripheral, cord and placental 
blood were tested for malaria; (2) maternal blood tested 
for haemoglobin; (3) stool tested for intestinal para-
sites; and (4) neonate and placenta weighed at delivery. 
Blood slides were collected by a trained midwife, stained 
and examined the same day by a trained microscopist 
at 100× magnification, with 200 fields checked before 
recording a negative result. All slides were re-read by an 
experienced microscopist, blinded to original diagnosis. 
Discrepancies were resolved by a third blinded read-
ing. Participants found positive for malaria were treated 
according to national guidelines (i.e. from 2nd trimester, 
CQ 25 mg/kg × 3 days for vivax or SP 25 mg/kg × 1 day 
plus artesunate 4 mg/kg × 3 days for falciparum malaria). 
Haemoglobin was measured by attending midwife using 
a HemoCue point-of-care test (Ängelholm, Sweden). Par-
ticipants found anaemic were provided treatment accord-
ing to national guidelines (i.e. iron 120 mg plus folic acid 
0.8 mg daily for 3 months). Stool was examined for hel-
minths and intestinal protozoa by trained microscopists, 
using duplicate Kato-Katz thick smears prepared shortly 
after collection and allowed to clear for 45–60  min 
before examination [34]. Participants found positive were 
treated according to national guidelines (i.e. from 2nd tri-
mester, mebendazole 500 mg). Birthweight was measured 
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by attending midwife for all births within 1 h of delivery, 
using an electronic scale (Salter, Birmingham UK) accu-
rate to ±10  g and calibrated weekly [35]. Fresh placen-
tas were weighed by attending midwife, untrimmed and 
without blood expressed, using the same procedure [36]. 
Data were double-entered into Microsoft® Access 2000, 
with range and consistency checks to reduce transposi-
tion errors.
Case–control study
All reproductive-age female outpatients presenting with 
suspected malaria (i.e. fever or history of fever suspected 
to be malaria) and providing informed consent, were 
enrolled between September 2004 and January 2005 at 
basic health facilities with malaria diagnostics and staff 
willing to participate in a study. All patients were exam-
ined by clinic doctors and clinical diagnosis, age, marital 
status, number of children, and number of previous preg-
nancies recorded on standardized forms. Controls were 
defined as WRA with clinically-suspected malaria, nega-
tive blood slides and no recent history of malaria (i.e. to 
exclude recently-treated patients). Cases were defined as 
WRA with microscopically confirmed malaria and cate-
gorized according to malaria species and severity. Severe 
cases were defined as parasitaemic, with one or more 
WHO indicators for severe malaria and absence of iden-
tified alternative causes [37]. Microscopy, treatment, and 
data entry replicated delivery survey protocols.
Community survey
Multi-stage sampling was used: (1) four districts were 
selected with functioning community health infrastruc-
ture (i.e. Shinwar, Mohmand Dara, Batikot, Nazian); (2) 
villages were identified within each district that were 
malaria-endemic, with antenatal services, and accessi-
ble by four-wheel drive vehicle; (3) all pregnant women 
in each village were invited to participate. Sample size 
was calculated to detect a malaria prevalence of 5 % with 
80 % power and 95 % confidence. Two collection periods, 
May–June and December 2004, incorporated seasonal 
peaks of vivax and falciparum transmission respec-
tively. Those providing informed consent were tested for 
malaria and anaemia and answered a structured ques-
tionnaire. Adapted from previous research [32], the ques-
tionnaire was back-translated in Pashtu and piloted in a 
non-participating district. Literate female interviewers 
were recruited from local communities and trained over 
3 days on privacy, prompting, and questionnaire comple-
tion. Microscopy, treatment, and data entry replicated 
delivery survey protocols.
Analysis
Data was analysed using Stata/IC13.1.
Delivery‑ward survey
Malaria infection was categorized as negative (i.e. nega-
tive peripheral, umbilical, and placental slide result) or 
positive (i.e. any positive result). Anaemia was catego-
rized as non-anaemic (i.e. 110  g/l or above) or anaemic 
(i.e. below 110  g/l) [38]. Birthweight was categorized 
as non-LBW (i.e. 2500  g or above) or LBW (i.e. below 
2500  g). Intestinal parasites were categorized as absent 
(i.e. none detected) or present (i.e. detection of any hel-
minth or protozoa). Logistic regression was used to cal-
culate odds ratios of anaemia or LBW outcomes, with 
univariate regression providing crude estimates and mul-
tivariate regression adjusting for a priori confounders (i.e. 
age, gravidity, presence of intestinal parasites). Cell sizes 
below 30 prompted exact logistic methods. Effect modi-
fiers (i.e. significant LRT test) were reported individually.
Case–control study
Categorization and analysis replicated delivery survey 
protocols. Additionally, ITN usage was defined as report-
ing sleeping under ITNs the previous night. Logistic 
regression calculated odds ratios of exposures. A priori 
confounders were district, facility, age, and parity.
Community survey
Categorization and analysis replicated delivery survey 
protocols. Additionally, participant age, education, hous-
ing, and household asset variables were weighted and 
scored within a socioeconomic status (SES) index using 
principal components analysis [32, 39]. Logistic regres-
sion calculated odds ratios of anaemia. A priori con-
founders were SES, district, age, parity, trimester, and 
season.
Ethics
Approval was provided by the Ministry of Public Health 
in Afghanistan and the Research Ethics Committee of 
the London School of Hygiene and Tropical Medicine in 
the UK (reference 5508). All participants were informed 
about the study purpose, content and potential pub-
lication and written or verbal informed consent was 
recorded. Data was coded anonymously and stored in 
password-protected hard-drives.
Results
Delivery‑ward survey
In total, 517 patients agreed to participate. Average age 
was 25  years (range 16–40). Approximately 35  % were 
primigravida, 31  % multigravida (2–4 pregnancies) and 
33  % grand-multigravida (5+ pregnancies). Among 38 
women with intestinal parasites (prevalence 74/1000, 
95  % CI 54–99), most frequent were Entamoeba his-
tolytica (47  %), Giardia lamblia (26  %) and Ascaris 
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lumbricoides (16  %). One malaria case (prevalence 
1.9/1000, 95  % CI 0.3–13.7), 179 anaemia cases (preva-
lence 346/1000, 95  % CI 306–388), and 59 low-birth-
weight (LBW) deliveries (114/1000, 95  % CI 89–115) 
were recorded.
As only one malaria case was detected, further analysis 
only compared factors associated with anaemia and LBW 
(Table 1). Anaemia presence was not associated with age, 
gravidity, presence of intestinal parasites, or LBW deliv-
ery. LBW delivery was not associated with intestinal par-
asite or anaemia presence, though it was associated with 
gravidity in multivariate analysis.
Case–control study
In total, 141 malaria cases and 1010 controls were 
enrolled from reproductive-age women attending eight 
district clinics (Table 2). Most were resident in Jalalabad 
(40  %), Shinwar (23  %) and Momand Dara (15  %) dis-
tricts. Average age was 28 (range 15–45). Most (81  %) 
were married. Approximately 25 % were nulliparous, 38 % 
had delivered 1–5 times, and 36 % more than five times. 
Parous women averaged five children (range 1–13). 
Approximately 25 % of women were pregnant and 23 % 
anaemic. Plasmodium falciparum infection accounted 
for 37 % (52/141) of malaria cases, 25 % (13/52) of which 
were assessed as severe. Among pregnant women, 
11  % (31/286) had malaria infection compared to 15  % 
(110/755) of non-pregnant women. Among pregnant 
women with malaria, 35 % (11/31) were infected with P. 
falciparum, of which one was severe.
Reported ITN usage was 32  % (45/141) among cases 
and 43 % (431/1010) among controls, giving a protective 
40  % lower odds of malaria infection (AOR 0.60; 95  % 
CI 0.40–0.91). None of age, pregnancy status, parity, or 
anaemia were associated with malaria infection in uni-
variate or multivariate analyses (Table 2).
Community survey
Socioeconomic and clinical variables
In total, 530 pregnant women participated. Mean age 
was 28 (range 15–45) and 80 % had no formal education. 
Most households averaged 10 members (range 1–39), 
three under age five (range 0–18), living in three rooms 
(range 1–12). Most had no electricity (73  %; 387/530), 
while 48  % owned land (255/530). Table  3 shows edu-
cation, employment and household assets used for 
principle components analysis, disaggregated by socio-
economic quartile.
Malaria point prevalence was 3.8/1000 (95  % CI 0.9–
15.0), anaemia was 277/1000 (95  % CI 241–317), and 
severe anaemia 34/1000 (95 % CI 21–53), similar to deliv-
ery-ward survey findings. As only two malaria cases were 
detected, analysis of effects on maternal haemoglobin 
concentration was conducted for anaemia instead. 
Table  4 shows none of age, parity, trimester, malaria 
infection, iron/folate usage, antenatal attendance, ITN 
usage, or SES were associated with anaemia in multivari-
ate analysis.
Knowledge/perceptions
Malaria knowledge was high, with 99 % reporting fever, 
shivering/chills, headache, weakness or joint pain as 
symptoms, 97  % reporting mosquito bites transmit 
malaria, 70  % reporting diagnosis by blood test, and 
81  % reporting ITN usage as the best available preven-
tion. Risk perception was also high, with 85 % proposing 
malaria as their community’s ‘worst health problem,’ 90 % 
as common in their community, and 38 % reporting they 
had experienced ‘malaria’ during their present pregnancy. 
In contrast, only 6 % identified either diarrhoeal disease 
or acute respiratory tract infections as concerns, despite 
high frequency of both (Table 5).
Reported practices
Most (76  %) reported NGO-run public-sector facilities as 
their primary source of healthcare. Most (86  %) reported 
attending antenatal services at least once during pregnancy, 
though only 42 % (223/530) reported attending 3–4 times as 
recommended by national guidelines. Only 27 % reported 
taking iron/folate during pregnancy, with 55 % reporting no 
use of dietary supplements. However, this differed by SES, 
with wealthier women having almost double the odds of 
taking iron/folate (AOR 1.90; 95 % CI 1.17–3.09).
Most (78 %) reported using public facilities for malaria 
treatment, primarily due to affordability (45 %) and effec-
tiveness (40 %), with no differences by SES. Most (82 %) 
reported they would never take drugs to prevent malaria 
during pregnancy. Of almost half (43 %) reporting avoid-
ing all medicines during pregnancy, 55  % reported 
doing so because they might feel sick and 32 % because 
drugs—including anti-malarials—might be dangerous 
during pregnancy. Although most (81 %) recommended 
ITNs for malaria prevention, only 17 % reported this as 
their major advantage and most (81 %) identified avoid-
ing nuisance biting as most important. Approximately 
38 % reported household ownership of at least one ITN. 
Most women in ITN-owning households reported that 
everyone (35  %) or children (32  %) usually slept under 
ITNs. While 80 % reported not using an ITN the previ-
ous night, wealthier women had three times higher odds 
of having slept under one (AOR 3.09; 95 % CI 1.01–9.51).
Discussion
Prevalence and perceptions
This study design, by using three distinct data sources 
to examine the scope of the problem in Afghanistan, 
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provides a broad view of malaria and anaemia in preg-
nancy. It is clear that factors other than malaria are chiefly 
responsible for the high prevalence of maternal anaemia 
detected in delivery-ward and cross-sectional surveys. 
Malaria prevalence of only 3.9/1000 among pregnant 
women in communities and 1.9/1000 in a delivery-ward, 
while still warranting concern, appears to reflect a genu-
ine reduction in malaria transmission rates in Afghani-
stan [31]. While not directly comparable, community 
survey data indicates malaria prevalence among all age 
groups in eastern Afghanistan has fallen from typically 
recorded prevalence of 7–10  % for vivax and 2–5  % for 
falciparum malaria in 2000 to approximately 0.16  % for 
vivax and 0.01 % for falciparum in 2013 [33, 40]. Reasons 
for this apparent reduction could include expansion of 
health services [23, 30], increased availability of malaria 
diagnosis and treatment [41], enhanced control activities 
[40, 42], improved political stability and socioeconomic 
development [30], and/or changing environmental condi-
tions and improved agricultural practices [28].
While recorded malaria prevalence was low, the high 
prevalence of maternal anaemia—consistent with a 
reported national prevalence of 40.3 % among WRA—is 
a concern [43]. However, associations between anaemia 
and malaria were not observed. More likely contributors 
were poor diet, lack of access to nutritional supplements 
during pregnancy, and poor spacing and high frequency 
of pregnancies [40]. Intestinal parasite prevalence was 
Table 1 Associations of  demographic and  clinical variables with  maternal anaemia and  low-birthweight delivery 
among 517 delivery-ward patients in eastern Afghanistan
* p < 0.05; ** p < 0.001; AOR adjusted for age, gravidity, intestinal parasite presence. Cell sizes below 30 use exact logistic methods
Associations with anaemia Anaemic, n (%) Non‑anaemic, n (%) OR (95 % CI) AOR (95 % CI)
(N = 179) (N = 338)
Age group
 15–20 66 (36.9) 143 (42.3) Ref. Ref.
 21–30 84 (46.9) 154 (45.6) 1.18 (0.80–1.75) 1.00 (0.63–1.60)
 31–49 29 (16.2) 41 (12.1) 1.53 (0.88–2.68) 1.20 (0.59–2.44)
Gravidity
 Primigravidous 54 (30.2) 129 (38.2) Ref. Ref.
 Multigravidous (2–4) 58 (32.4) 104 (30.8) 1.33 (0.85–2.09) 1.32 (0.81–2.17)
 Grand-multigravidous (5+) 67 (37.4) 105 (31.1) 1.52 (0.98–2.37) 1.42 (0.80–2.53)
Intestinal parasites
 No 167 (93.3) 312 (92.3) Ref. Ref.
 Yes 12 (6.7) 26 (7.7) 0.86 (0.42–1.75) 0.82 (0.40–1.67)
LBW
 No 159 (88.8) 229 (88.5) Ref. Ref.
 Yes 20 (11.2) 39 (11.5) 0.96 (0.54–1.71) 1.09 (0.60–1.97)
Associations with LBW LBW, n (%) Non‑LBW, n (%) OR (95 % CI) AOR (95 % CI)
(N = 59) (N = 458)
Age
 15–20 33 (55.9) 176 (38.4) Ref. Ref.
 21–30 21 (35.6) 217 (47.4) 0.52 (0.29–0.92)* 1.13 (0.57–2.22)
 31–49 5 (8.5) 65 (14.2) 0.41 (0.15–1.10) 2.17 (0.55–8.49)
Gravidity
 Primigravidous 38 (64.4) 145 (31.7) Ref. Ref.
 Multigravidous (2–4) 13 (22.0) 149 (32.5) 0.33 (0.17–0.64)** 0.31 (0.15–0.64)**
 Grand-multigravidous (5+) 8 (13.6) 164 (35.8) 0.19 (0.08–0.41)** 0.13 (0.04–0.39)**
Intestinal parasites
 No 55 (93.2) 424 (92.6) Ref. Ref.
 Yes 4 (6.8) 34 (7.4) 0.90 (0.31–2.65) 1.04 (0.34–3.14)
Anaemia
 No 39 (66.1) 299 (65.3) Ref. Ref.
 Yes 20 (33.9) 159 (34.7) 0.96 (0.54–1.70) 1.09 (0.60–1.96)
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Table 2 Associations between demographic and clinical exposures and malaria, among 1150 case–control study partici-
pants in eastern Afghanistan
 * p < 0.05; AOR adjusted for district, facility, age, parity
Variables Cases, n (%) Controls, n (%) OR (95 % CI) AOR (95 % CI)
(N = 141) (N = 1010)
Age group
 15–20 32 (22.7) 286 (28.3) Ref. Ref.
 21–30 62 (44.0) 437 (43.3) 1.27 (0.81–1.99) 1.36 (0.74–2.49)
 31–49 47 (33.3) 287 (28.4) 1.46 (0.91–2.36) 1.49 (0.75–2.97)
Pregnant 31 (22.0) 255 (25.3) 0.83 (0.55–1.27) 0.89 (0.56–1.42)
Parity
 Nulliparous (no births) 36 (25.5) 256 (25.4) Ref. Ref.
 Parous (1–5 births) 55 (39.0) 389 (38.5) 1.01 (0.64–1.57) 0.84 (0.47–1.52)
 Grand-multiparous (6+ births) 50 (35.5) 365 (36.1) 0.97 (0.62–1.54) 0.68 (0.35–1.31)
Anaemic 33 (23.4) 230 (22.8) 1.04 (0.68–1.57) 1.00 (0.65–1.54)
ITN usage 45 (32.0) 431 (42.7) 0.63 (0.43–0.92)* 0.60 (0.40–0.91)*
Table 3 Factors used in principle components analysis to define socioeconomic quartiles among 530 community survey 
participants in eastern Afghanistan
Socioeconomic variables Socioeconomic quartile, n (%)
1. Poorest (N = 133) 2. Poor (N = 132) 3. Less poor (N = 133) 4. Least poor (N = 132)
Education
 None 128 (30.2) 109 (25.8) 100 (23.6) 87 (20.5)
 Religious/informal 3 (5.4) 15 (26.8) 18 (32.1) 20 (35.8)
 Primary-school 2 (9.1) 6 (27.3) 3 (13.6) 11 (50.0)
 Middle-school 0 (0) 1 (8.3) 4 (33.3) 7 (58.3)
 High-school 0 (0) 1 (6.7) 8 (53.3) 6 (40.0)
 University/technical 0 (0) 0 (0) 0 (0) 1 (100)
Primary earner’s employment
 Not working 2 (40.0) 2 (40.0) 1 (20.0) 0 (0)
 Manual labour 70 (37.6) 46 (24.7) 43 (23.1) 27 (14.5)
 Farming 35 (22.0) 48 (30.2) 34 (21.4) 42 (26.4)
 Trade/market 14 (18.0) 22 (28.2) 20 (25.6) 22 (28.2)
 Driver 8 (18.1) 10 (22.7) 11 (25.0) 15 (34.1)
 Office/similar 4 (7.0) 4 (7.0) 24 (41.4) 26 (44.9)
Household assets
 Guestroom 28 (9.3) 70 (23.3) 91 (30.2) 112 (37.2)
 Electricity 11 (7.4) 29 (19.7) 43 (29.3) 64 (43.5)
 Land ownership 33 (13.0) 64 (25.1) 61 (24.0) 97 (38.0)
 Car/truck 0 (0) 2 (4.0) 12 (24.0) 36 (72.0)
 Radio/music-player 5 (4.2) 15 (12.7) 30 (25.4) 68 (57.6)
 Rug 12 (6.6) 33 (18.2) 60 (33.2) 76 (42.0)
 Curtains 18 (7.1) 57 (22.4) 71 (28.0) 108 (42.5)
 Bicycle 25 (12.1) 38 (18.4) 60 (29.0) 84 (40.6)
 Pressure-cooker 27 (8.3) 79 (24.2) 101 (31.0) 119 (36.5)
 ITNs 9 (4.5) 31 (15.6) 65 (32.7) 94 (47.2)
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higher than the 3.8 % reported among pregnant women 
in the 2013 National Nutrition Survey [43]. LBW preva-
lence was lower than the Unicef estimate of 28 % for the 
South Asia region, though comparable data was unavail-
able for Afghanistan [44].
Perceptions of malaria risk appeared higher than war-
ranted by a prevalence of 1.9–3.8/1000. It is unlikely that 
most of the 38 % reported malaria in the community sur-
vey was actually malaria, and it was not associated with 
anaemia prevalence. Both Leslie et al. and Reynolds et al. 
found febrile illness was often erroneously clinically diag-
nosed as malaria, while Howard et al. found that malaria 
and typhoid were often identified interchangeably in 
communities [41, 45, 46]. It should also be noted that 
women were aware that the survey focused on malaria, 
and reporting it as a ‘major health concern’ could 
have reflected both perceived risk and some potential 
response bias. Perceptions perhaps predated health sys-
tem strengthening and/or were encouraged by popular 
misconceptions that non-specific febrile illness was often 
malarial [41, 45]. Despite minimal educational attain-
ment, women were knowledgeable about malaria, prob-
ably reflecting long-running health education efforts by 
NGOs since the 1990s [46]. Growing evidence indicates 
Table 4 Associations of socioeconomic, clinical and behavioural responses with anaemia among 530 community survey 
participants in eastern Afghanistan
 * p < 0.05; AOR adjusted for survey, age, parity, trimester, SES, district; Cell sizes below 30 use exact logistic methods
Variables Hb Anaemic, n (%) Non‑anaemic, n (%) OR (95 % CI) AOR (95 % CI)
Mean ± SD (range) (N = 147) (N = 383)
Age
 15–20 11.4 ± 1.9 (7.3–19.3) 22 (15.0) 78 (20.4) Ref. Ref.
 21–30 11.0 ± 1.7 (6.5–17.5) 81 (55.1) 223 (58.2) 1.29 (0.75–2.20) 1.35 (0.71–2.57)
 31–45 10.7 ± 1.7 (6.5–15.5) 44 (29.9) 82 (21.4) 1.90 (1.05–3.46)* 1.89 (0.85–4.20)
Parity
 Nulli/primiparous (0–1 births) 11.1 ± 1.8 (6.8–17.5) 35 (23.8) 103 (27.0) Ref. Ref.
 Multiparous (2–5 births) 10.9 ± 1.7 (6.5–19.3) 76 (51.7) 187 (48.8) 1.20 (0.75–1.90) 0.99 (0.57–1.72)
 Grand-multiparous (6+ births) 10.9 ± 1.7 (6.5–14.7) 36 (24.5) 93 (24.3) 1.14 (0.67–1.96) 0.76 (0.38–1.52)
Trimester
 1st 10.9 ± 2.1 (8.0–14.0) 3 (2.0) 6 (1.58) Ref. Ref.
 2nd 11.3 ± 1.7 (7.0–17.5) 57 (38.8) 188 (49.1) 0.61 (0.15–2.50) 0.53 (0.12–2.41)
 3rd 10.7 ± 1.7 (6.5–19.3) 87 (59.2) 189 (49.4) 0.92 (0.22–3.77) 0.76 (0.17–3.41)
Malaria infection
 No 11.0 ± 1.7 (6.5–19.3) 147 (100) 381 (99.5) – –
 Yes 12.5 ± 1.4 (11.5–14) 0 (0) 2 (0.5) – –
Iron/folate usage
 No 10.9 ± 1.7 (6.5–19.3) 108 (73.5) 277 (72.3) Ref. Ref.
 Yes 11.1 ± 1.7 (6.7–15.5) 39 (26.5) 106 (27.7) 0.94 (0.61–1.44) 1.16 (0.73–1.84)
Antenatal attendance (at least once)
 No 11.0 ± 1.4 (6.9–17.5) 20 (13.6) 54 (14.1) Ref. Ref.
 Yes 11.0 ± 1.7 (6.5–19.3) 127 (86.4) 329 (85.9) 1.04 (0.60–1.81) 1.03 (0.57–1.87)
Household ITN ownership
 No 11.0 ± 1.8 (6.5–19.3) 91 (61.9) 240 (62.7) Ref. Ref.
 Yes 11.1 ± 1.7 (6.5–15.5) 56 (38.1) 143 (37.3) 1.03 (0.70–1.53) 1.74 (0.99–2.90)
Slept under ITN last night
 No 11.0 ± 1.4 (6.5–19.3) 134 (91.2) 357 (93.2) Ref. Ref.
 Yes 10.8 ± 1.4 (8.6–14.2) 13 (8.8) 26 (6.8) 1.33 (0.66–2.67) 1.71 (0.82–3.64)
Socioeconomic status
 1. Poorest 10.8 ± 1.9 (6.5–17.5) 47 (32.0) 86 (22.5) Ref. Ref.
 2. Poor 10.9 ± 1.8 (6.8–19.3) 35 (23.8) 97 (25.3) 0.66 (0.39–1.12) 0.72 (0.41–1.26)
 3. Less poor 10.9 ± 1.7 (6.5–14.3) 39 (26.5) 94 (24.5) 0.76 (0.45–1.27) 0.95 (0.53–1.71)
 4. Least poor 11.4 ± 1.6 (7.5–15.5) 26 (17.7) 106 (27.7) 0.45 (0.26–0.78)* 0.57 (0.29–1.10)
Page 8 of 11Howard et al. Malar J  (2015) 14:431 
Table 5 Associations of knowledge and behavioural responses with socioeconomic status among 530 community survey 
participants in eastern Afghanistan
Response variables Poorera Wealthiera OR (95 % CI) AOR (95 % CI)
(N = 265) (N = 265)
Primary source of healthcare
 NGO/government health facility 217 (81.9) 184 (69.4) Ref. Ref.
 Private health facility 43 (16.2) 67 (25.3) 1.84 (1.19–2.82)* 1.30 (0.77–2.21)
 Traditional/self-treat 5 (1.9) 14 (5.3) – –
Attended antenatal services at least once 228 (86.0) 228 (86.0) 1.00 (0.61–1.63) 1.38 (0.75–2.54)
Uses iron/folate supplements 54 (20.45) 91 (34.3) 2.34 (1.55–3.53)* 1.90 (1.17–3.09)*
Greatest health concern
 Other 3 (1.1) 10 (3.8) – –
 Diarrhoea 18 (6.8) 14 (5.3) Ref. Ref.
 ARI 12 (4.5) 21 (7.9) 0.53 (0.12–2.29) 0.53 (0.09–3.03)
 Malaria 232 (87.6) 220 (83.0) 0.28 (0.77–1.05) 0.43 (0.91–2.00)
How common is malaria
 No malaria/infrequent 22 (8.3) 29 (10.9) Ref. Ref.
 Common 243 (91.7) 236 (89.1) 0.74 (0.41–1.32) 0.73 (0.36–1.48)
Best malaria prevention in pregnancy
 Nothing works 29 (10.9) 24 (9.1) Ref. Ref.
 ITNs 212 (80.0) 219 (82.6) 1.25 (0.70–2.21) 1.26 (0.64–2.46)
 Rapid diagnosis/treatment 1 (0.4) 1 (0.4) – –
Burning/smoke 8 (3.0) 9 (3.4) – –
Clean house/area 15 (5.7) 12 (4.5) 0.97 (0.38–2.46) 0.53 (0.17–1.64)
Preferred malaria diagnosis
 Self/informal 31 (11.7) 48 (18.1) Ref. Ref.
 Facility (clinical) 50 (18.9) 29 (10.9) 0.37 (0.20–0.71)* 0.43 (0.19–0.96)*
 Facility (blood test) 184 (69.4) 188 (70.9) 0.66 (0.40–1.08) 0.91 (0.48–1.72)
Preferred malaria treatment
 NGO/government health facility 214 (80.8) 198 (74.2) Ref. Ref.
 Private health facility/Other 51 (19.2) 67 (25.3) 1.42 (0.94–2.14) 0.86 (0.51–1.44)
Would use malaria-preventive drugs in pregnancy
 Never 232 (87.6) 204 (77.0) Ref. Ref.
 Yes/maybe 33 (12.5) 61 (23.0) 2.10 (1.32–3.34)* 1.69 (0.98–2.91)
Why use ITNs
 Avoid mosquitoes 169 (63.8) 167 (63.0) Ref. Ref.
 Prevent insect bites 49 (18.5) 43 (16.2) 0.89 (0.56–1.41) 1.15 (0.65–2.02)
 Prevent malaria 40 (15.1) 51 (19.3) 1.29 (0.81–2.06) 1.92 (1.07–3.43)*
Other/don’t know 7 (2.6) 4 (1.5) – –
ITN‑owners only n = 40 (%) n = 159 (%)
Which family members use ITNs
 Nobody/unknown 11 (27.5) 41 (25.8) Ref. Ref.
 All 9 (22.5) 61 (38.4) 1.82 (0.69–4.78) 1.23 (0.37–4.04)
 Children 20 (50.0) 43 (27.0) 0.58 (0.24–1.35) 0.48 (0.16–1.40)
 Women 0 (0) 11 (6.9) – –
 Men/elderly 0 (0) 3 (1.9) – –
Participant used ITN last night 7 (17.5) 32 (20.1) 1.19 (0.48–2.93) 3.09 (1.01–9.51)*
Reasons for not using ITN last night n = 33 (%) n = 127 (%)
No mosquito nuisance 11 (33.3) 35 (27.6) Ref. Ref.
ITN used by others 12 (36.4) 26 (20.5) 0.68 (0.26–1.78) 2.87 (0.42–19.8)
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messages have been effective, despite low literacy and 
cultural constraints targeting most efforts at men [32, 
46].
Policy and practice implications
This study demonstrated that the risk of malaria in 
pregnancy is low among Afghan women. However, the 
malaria burden among pregnant women in Afghanistan 
remains sufficient to warrant specific action. Plasmodium 
vivax treatment is particularly challenging in pregnancy. 
While blood-borne parasites respond to chloroquine or 
sulfadoxine–pyrimethamine, both safe in pregnancy [47], 
vivax infections often relapse without radical primaquine 
treatment [48]. Pregnant and lactating women cannot 
receive primaquine, due to risks of haemolytic anaemia 
in glucose-6-phosphate dehydrogenase (G6PD) deficient 
foetuses [22]. Pregnant women thus risk repeated clini-
cal episodes throughout pregnancy and lactation, as well 
as pre-term, miscarried, and LBW deliveries [1, 4, 6, 
10–15, 19, 20]. Given the challenges of infection in preg-
nancy, prevention is clearly preferable. The two preven-
tion approaches advocated by WHO in pregnancy are (1) 
ITN/LLINs, and (2) intermittent preventive treatment 
in pregnancy (IPTp), providing a full therapeutic anti-
malarial course during antenatal visits.
Which approach would be most effective and accept-
able for Afghanistan? ITN/LLINs demonstrated 40  % 
malaria protection in the case–control study, similar to 
protection demonstrated for Afghan refugee populations 
in neighbouring Pakistan [49]. Additionally, the com-
munity survey confirmed ITN/LLINs were popular and 
used by all family members [32, 33]. Conversely, persuad-
ing pregnant women to take IPTp could be challenging 
given the perceived risks of taking medication during 
pregnancy. Weighing the limited risk of malaria in preg-
nancy, demonstrable protection and popularity of LLINs, 
Fig. 1 Map of Afghanistan showing Nangarhar and Laghman Provinces. Adapted from Tubbs, https://en.wikipedia.org/wiki/Nangarhar_Province#/
media/File:Nangarhar_in_Afghanistan.svg
Table 5 continued
Reasons for not using ITN last night n = 33 (%) n = 127 (%)
No reason provided 10 (30.3) 66 (52.0) 2.07 (0.80–5.36) 4.65 (1.09–19.8)*
 * p < 0.05; AOR adjusted for survey, age, parity, trimester, district
a Poorer merges SEQ 1 and 2, Wealthier merges SEQ 3 and 4
Page 10 of 11Howard et al. Malar J  (2015) 14:431 
reported avoidance of drugs during pregnancy, and still 
relatively limited data on IPTp for vivax malaria, there 
seems no real justification to initiate an IPTp strategy in 
Afghanistan. ITNs/LLINs are a proven preventive strat-
egy, which along with rapid diagnosis and treatment, 
can help protect pregnant women in low-endemicity 
countries such as Afghanistan [33]. Universal coverage 
with ITNs/LLINs, such as the Global Fund supported 
initiative providing free LLINs to pregnant women and 
immunized children, should be the preventive strategy of 
choice for pregnant women in Afghanistan.
Less than half of community survey participants 
reported household ownership of any ITNs and only 
20  % reported using ITNs the previous night, irrespec-
tive of season or socioeconomic status. Since this study 
universal LLIN coverage campaigns have increased cov-
erage to approximately 80  % of high-risk populations 
[40]. LLINs can be used for an average 3–5 year lifespan 
without retreatment, and since 2005 WHO has recom-
mended programmes only purchase and distribute LLINs 
[50]. Health messages should emphasize that LLINs be 
used by all family members, particularly those at greatest 
risk from malaria. That over 80  % of women cited pre-
vention of nuisance biting as more relevant than malaria 
prevention is not necessarily negative, as families do use 
ITNs appropriately when given access [31].
Despite the benefits of ITNs, they may not be sufficient 
to reduce malaria in pregnancy on their own, as 32 % of 
malaria cases in the case–control study used ITNs. Inter-
mittent screening and treatment in pregnancy (ISTp), 
during routine antenatal visits, has shown some promise 
in other settings and could be considered [51–54]. How-
ever, as malaria is normally symptomatic in Afghanistan 
and women seek treatment promptly, the benefits of add-
ing ISTp to antenatal services would likely be relatively 
small even with increased antenatal attendance. National 
antenatal guidelines currently recommend that women in 
malarious areas be advised on prompt treatment seeking 
and usage of ITNs [55]. Thus, policy recommendations 
on ISTp would only be possible after research on accept-
ability, costs, and effectiveness.
Limitations
Low malaria prevalence limited analysis of associations. 
Reliance on prevalence data during pregnancy can under-
estimate malaria incidence risk in low transmission areas, 
as described by Rijken et al., and longitudinal calculation 
of cumulative incidence would have been preferable [6]. 
Additionally, community sampling may have underesti-
mated malaria prevalence if those ill at home did not par-
ticipate. However, comparison of facility and community 
samples produced no evidence of bias, indicating surveys 
reflected transmission. Use of febrile outpatient rather 
than community controls is a limitation, as controls may 
have been previously parasitaemic. A population control, 
though preferable, was not feasible.
Conclusions
Malaria did not appear responsible for the high preva-
lence of maternal anaemia detected. While malaria 
prevalence was low, the risk of severe malaria among 
pregnant women is sufficient in Afghanistan to justify 
specific preventive interventions. Given women’s per-
ceptions of drug usage in pregnancy and the limited 
transmission risk, an IPTp implementation strategy is 
not justified. Scaling-up LLINs, with increased MOPH 
emphasis on usage in pregnancy, is likely to be more suc-
cessful in Afghanistan.
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